1. Clinical selection according to the Amsterdam II criteria and revised Bethesda guidelines. 1,2 2. Study of MMR function in tumour cells 3, 4 : Immunohistochemical (IHC) study of the four mismatch repair proteins MLH1, MSH2, MSH6, and PMS2. In case of absence of the MLH1 protein, BRAF codon 600 characterisation by pyrosequencing, sequencing, TaqMan, SNaPshot, and so on and somatic methylation analysis of the MLH1 promotor could help to distinguish sporadic from Lynch-associated cancers. In case of an ambiguous result in immunohistochemistry, microsatellite DNA analysis -genotyping of the consensus panel of five mononucleotidic repeats defined in 1998 should be performed additionally 5 (pathogenic missense mutation might be missed without microsatellite analysis 6 ). May vary with national settings. 3. Germline analysis 7, 8 9 Germline MLH1 promoter methylation characterisation by MSP, bisulphite pyrosequencing, or MLPA (useful for diagnostic purpose, not for predictive testing).
Analytical validation
Confirmation of mutation in an independent biological sample of the index case or an affected relative. In case of deletion/duplication of one exon, confirm with a second technique/kit based on different primers.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence) Prevalence in colorectal cancer patients about 1-3%. 10 Estimated prevalence in population about 1:660 
Negative predictive value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Almost 100%.
(in case of mutation analysis in the coding area, common splice sites, large genomic deletions/duplications).
Analytical specificity (proportion of negative tests if the genotype is not present)
Almost 100%.
Assuming a complete screening of all genes.
Variants of unknown significance might be re-classified as deleterious a posteriori.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Not high. Dependent on the indication criteria and the molecular strategy used (primary screening with MSI and IHC or not).
Computed by predictive models. 12 
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Unknown. The test has no clinical specificity that goes beyond the analytical specificity (see 2.2) since it is not a test for cancer but for cancer risk.
Positive clinical predictive value (life-time risk to develop the disease if the test is positive)
Up to B80%. Dependent, for example, on the affected MMR gene and gender. 13 
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: The index case in a family has usually already developed cancer before the genetic test.
Index case in that family had not been tested: This is an unusual and not recommended approach. Likely, but no consensus reached yet. 14 
CLINICAL UTILITY

Prognosis (please describe)
CRCs with MSI have a significantly better prognosis compared with those with intact mismatch repair. 15 
Management (please describe)
Offer for prophylactic hysterectomy and bilateral salpingo-oophorectomy in women who have a pathogenic germline mutation for Lynch syndrome as an option for cancer prevention after a woman's family is completed. 16, 17 Method of operation (e.g., segmental resection versus total colorectal resection with ileorectal anastomosis in case of colorectal cancer). 13 May vary with national settings.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked) 
